XSHE
300358
Market cap1.00bUSD
Oct 09, Last price
9.47CNY
1D
0.85%
1Q
16.77%
Jan 2017
-45.07%
IPO
-10.07%
Name
Truking Technology Ltd
Chart & performance
Notes
No notes on this company yet
Write a private note on this company, for your eyes only
Profile
Truking Technology Limited, established in 2000 and headquartered in Changsha, China, specializes in the research, development, and innovation of machinery for the pharmaceutical and medical industries. The company delivers end-to-end manufacturing solutions for diverse sterile products, encompassing lyophilization, injectable ampoules and vials (for both liquid and powder forms), pre-filling and sealing operations, plastic bottle blow-fill-seal technology, cartridges, non-PVC soft bags, and glass infusion bottles. Its offerings also include specialized fluid processing systems, advanced isolating systems, and dedicated lyophilization laboratories. Operating with a significant international footprint, Truking Technology distributes its products to approximately 40 countries and regions across Asia, Europe, South America, and other global markets.
Key people
Yue Tang
Chairman of the Board, President · since 2010
Fanyun Zeng
Chief Executive Officer, Vice Chairman of the Board · since 2024
Yuanlong Zhong
Co-President · since 2024
Yunhong Xiao
Chief Financial Officer, Director, Financial President · since 2022
Jingying Zhou
President - Human Resources and Administration · since 2022
Shui Liu
Chief Human Resource Officer, Senior Vice President · since 2024
Hui Hu
Senior Management Officer · since 2024
Yuting Huang
Secretary of the Board · since 2024
Director · since 2022
Lang Li
Staff Elected Director · since 2025
Guilin Liu
Director · since 2025
Yongmou Qiu
Director · since 2025
Wenlu Yang
Senior Management, Director · since 2024
Feiyue Zhou
Vice President, Director · since 2024
Shanping Wang
Independent Director · since 2022
Ping Wei
Independent Director · since 2022
Independent Director · since 2022
Independent Director · since 2022
Zaoping Zhang
Independent Director · since 2022
Valuation
Title CNY in thousands, except ratios and share amounts | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY | FY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2025‑12 | 2024‑12 | 2023‑12 | 2023‑00 | 2022‑12 | 2022‑00 | 2021‑12 | 2020‑12 | 2019‑12 | 2018‑12 | 2017‑12 | 2016‑12 | |
| Income | ||||||||||||
Revenues | ||||||||||||
Cost of revenue | ||||||||||||
Unusual Expense (Income) | ||||||||||||
NOPBT | ||||||||||||
NOPBT Margin | ||||||||||||
Operating Taxes | ||||||||||||
Tax Rate | ||||||||||||
NOPAT | ||||||||||||
Net income | ||||||||||||
Dividends | ||||||||||||
Dividend yield | ||||||||||||
Proceeds from repurchase of equity | ||||||||||||
BB yield | ||||||||||||
| Debt | ||||||||||||
Debt current | ||||||||||||
Long-term debt | ||||||||||||
Deferred revenue | ||||||||||||
Other long-term liabilities | ||||||||||||
Net debt | ||||||||||||
| Cash flow | ||||||||||||
Cash from operating activities | ||||||||||||
CAPEX | ||||||||||||
Cash from investing activities | ||||||||||||
Cash from financing activities | ||||||||||||
FCF | ||||||||||||
| Balance | ||||||||||||
Cash | ||||||||||||
Long term investments | ||||||||||||
Excess cash | ||||||||||||
Stockholders' equity | ||||||||||||
Invested Capital | ||||||||||||
ROIC | ||||||||||||
ROCE | ||||||||||||
| EV | ||||||||||||
Common stock shares outstanding | ||||||||||||
Price | ||||||||||||
Market cap | ||||||||||||
EV | ||||||||||||
EBITDA | ||||||||||||
EV/EBITDA | ||||||||||||
Interest | ||||||||||||
Interest/NOPBT | ||||||||||||